Atheronova Inc (AHRO) 2.2500 $AHRO
AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001
PR Newswire - Wed Jul 30, 6:00AM CDT
AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces that its partner, CardioNova, has accomplished first dosing of subjects for its Phase 1b clinical trial with AtheroNova's lead compound, AHRO-001. This Phase 1b trial will be a continuation of the AHRO-001 Phase 1 safety trial completed in February 2014, in which patients were dosed with AHRO-001 for up to three weeks. The Company will remain blinded to data from the earlier Phase 1 cohorts until the completion of Phase 1b, at which time the topline data will be presented together in approximately six to eight months.
AtheroNova files pre-IND under Section 505(b)(2) process for its bile acids platform
M2 - Wed Jul 16, 8:44AM CDT
Biotechnology company AtheroNova (Other OTC :AHRO) said on Tuesday that it has filed pre-Investigational New Drug (pre-IND) documents using a patented bile acid in combination with a statin for the treatment of patients who fail to reach their LDL cholesterol target with statin treatment alone.
AtheroNova Announces Pre-IND Filing Under Section 505(b)(2)
GlobeNewswire - Tue Jul 15, 7:22AM CDT
AtheroNova Inc. (OTCBB:AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announced that it has filed pre-Investigational New Drug (pre-IND) documents with the US Food and Drug Administration (the "FDA"
under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act (the "Act" using a patented bile acid, in combination with a statin for the treatment of patients who fail to reach their LDL cholesterol target with statin treatment alone. The Company has received its initial pre-IND file number from the FDA indicating the initiation of the review process. Section 505(b)(2) of the Act specifically allows the FDA to rely on data not developed by the applicant company for approval of a New Drug Application ("NDA" for their intent to use previously approved active ingredient(s) in a combination product or for a new indication not previously approved.
AtheroNova Announces 2013 Financial Results
GlobeNewswire - Thu Mar 06, 8:23AM CST
AtheroNova Inc. (OTCBB:AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announced its financial results for the year-ended December 31, 2013 and is providing a corporate update on operations and progress on lead candidate AHRO-001.
AtheroNova Announces Preliminary Positive Phase 1 Clinical Data From Lead Drug AHRO-001, a Potential Treatment for Atherosclerosis
GlobeNewswire - Thu Feb 27, 8:52AM CST
AtheroNova Inc. (OTCBB:AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announced the release of preliminary findings from its Phase 1 clinical trial with its lead compound, AHRO-001. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.
Liberty Software and VUCA Health Partner to Enhance Patient Safety and Provide Pharmacies with an Innovative Patient Engagement Tool
PR Newswire - Fri Jan 17, 8:08AM CST
VUCA Health, which has created the largest and most robust medication video library in the world to address health literacy, announced today that Liberty Software, a leading pharmacy management solution focused on innovation and customer service, will offer the MedsOnCue solution to its base of pharmacies.
Global Microspheres Market Report 2013 - Global Trends & Forecasts to 2018
PR Newswire - Wed Jan 08, 1:13PM CST
Research and Markets (http://www.researchandmarkets.com/research/6s2fj8/microspheres) has announced the addition of the "Global Microspheres Market Report 2013 - Global Trends & Forecasts to 2018" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
10-K: ESTERLINE TECHNOLOGIES CORP
Edgar Online - Fri Dec 20, 3:08PM CST
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations
Farmers Files Lawsuit Seeking More Than $3 Million Against Radiological Corporations And Their Owners For Allegedly Billing For Services Never Rendered
PR Newswire - Thu Dec 19, 10:32AM CST
Farmers Insurance Exchange®, 21st Century Insurance Company®, Coast National Insurance Company®, Mid-Century Insurance Company®, and Truck Insurance Exchange® ("Farmers" have filed a lawsuit in the Superior Court of California against two radiological corporations and their owners alleging they prepared and submitted false and misleading documentation to receive payment for services never provided. The detailed civil complaint seeks restitution and additional remedies for alleged violations of California's Unfair Business Practices (Business and Professions Code 17200) as well as the Insurance Frauds Prevention Act (Insurance Code 1871.7), and an order directing Defendants to cease and desist from engaging in alleged improper billing practices.
AtheroNova to Present at the 2013 Aegis Healthcare Conference in Las Vegas
PR Newswire - Thu Sep 19, 6:00AM CDT
AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announced that Chairman and CEO, Thomas W. Gardner, will present a corporate overview at the 2013 Aegis Capital Healthcare Conference. The presentation will take place at 9:00am PT on Saturday, September 28 at The Encore at Wynn in Las Vegas, NV.
AtheroNova Inc. Presenting at 15th Annual Rodman & Renshaw Investment Conference
Marketwire - Wed Sep 04, 12:08PM CDT
AtheroNova Inc. (OTCQB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announced it will be featured as a presenting company at the 15th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. AtheroNova will be presenting on Monday, September 9 at 12:05pm EDT. The conference is being held September 8-10, 2013, at the Millennium Broadway Hotel in New York City.
Medical Marijuana, Biotech and Precious Metals Micro-Caps Under the Radar
Marketwire - Tue Aug 27, 8:52AM CDT
Virtual Sourcing, Inc. (PINKSHEETS: PGCX) pursues business opportunities in fiberglass recycling and marketing manufactured products made from recycled fiberglass fibers, other fibers and virgin materials. PGCX has announced ambitious growth plans throughout the month of August. Read about them all at the following link: http://bit.ly/REPORTPGCX
OTC Daily Alert Stock Watch - AtheroNova Inc (OTCBB: AHRO )
WorldStockWire - Sat Aug 10, 8:00PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
AtheroNova, Amgen and More Leveraging Russian Initiatives to Grow Biotech Sector
ACCESSWIRE - Thu Jul 18, 9:00AM CDT
"Life is short, and the process is long." That's what Cleveland BioLabs (NASDAQ: CBLI) President Dr. Michael Fonstein told Forbes last year while discussing the U.S. Food and Drug Administration's regulatory process. Cleveland BioLabs shifted the development of several of their drugs from the U.S. to Russia, the birthplace of the company and a land where regulations are more flexible, in order to expedite the process towards commercialization.
AtheroNova's AHRO-001 Targets Much More than Cholesterol, Shows New UCLA Study
ACCESSWIRE - Tue Jul 02, 9:52AM CDT
Metabolic Syndrome ("MS" affects approximately a quarter of the U.S. population, according to a 2002 National Health and Nutrition Examination Survey. Characterized by raised triglycerides, reduced HDL cholesterol, high BMI/waistline, raised blood pressure, and raised fasting plasma glucose, the syndrome significantly increases the risk of heart disease and a host of other health problems, including stroke, diabetes and some common forms of cancer.
AtheroNova Announces Publication of Positive Pre-Clinical Results with AHRO-001 in the FASEB Journal
PR Newswire - Thu Jun 27, 7:00AM CDT
AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announced publication of the preclinical study that supported the clinical development of the Company's investigational AHRO-001 drug. The study, which was conducted by scientists at the David Geffen School of Medicine, University of California Los Angeles, was published in the June 10, 2013 online issue of the FASEB Journal in advance of the print issue.
AtheroNova Inc initiates Phase 1 clinical trial of AHRO-001 for the potential treatment of atherosclerosis
M2 - Wed Jun 26, 6:45AM CDT
Biotech company AtheroNova Inc (OTC Markets:AHRO) reported on Tuesday the launch of its milestone Phase 1 clinical trial with its lead compound, AHRO-001, for the potential treatment of atherosclerosis.
Combining Therapies to Amplify the Effects of Statins
ACCESSWIRE - Wed Jun 12, 8:51AM CDT
Statins, drugs that improve blood cholesterol levels by inhibiting the liver enzyme HMG Co-A reductase, are some of the most widely prescribed drugs in the United States. Increasing diabetes and obesity rates are real problem, resulting in doctors working the script pad like never before in the last decade. Three of the 20 best-selling drugs of all-time are statins used in the treatment of dyslipidemia, a condition where a person has an abnormally high amount of lipids (cholesterol or fat) in their blood.
AtheroNova Announces Shipment of Phase 1 Drug Product
PR Newswire - Thu May 30, 7:01AM CDT
AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and to improve lipid profiles in humans, today announced that it has shipped the necessary clinical supplies of AHRO-001 to its Russian licensing partner, CardioNova. This drug product shipment is the last major step prior to kickoff of a Phase I human clinical trial. The shipment has set forth a timeline with patient screenings and first-in-man dosing in June.
AtheroNova Mentioned by Analyst in Life Sciences Report
ACCESSWIRE - Fri May 24, 8:15AM CDT
Mont Blanc Capital Equity Research issued a research update on May 14, 2013 for AtheroNova Inc. (OTC Markets: AHRO). In the report, the analyst maintained its Buy rating and $2.00 per share price target, while projecting that Phase I clinical trials would begin next month after the company received approval from the Russian Ministry of Healthcare (Minzdrav).
AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001
PR Newswire - Wed Jul 30, 6:00AM CDT
AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces that its partner, CardioNova, has accomplished first dosing of subjects for its Phase 1b clinical trial with AtheroNova's lead compound, AHRO-001. This Phase 1b trial will be a continuation of the AHRO-001 Phase 1 safety trial completed in February 2014, in which patients were dosed with AHRO-001 for up to three weeks. The Company will remain blinded to data from the earlier Phase 1 cohorts until the completion of Phase 1b, at which time the topline data will be presented together in approximately six to eight months.
AtheroNova files pre-IND under Section 505(b)(2) process for its bile acids platform
M2 - Wed Jul 16, 8:44AM CDT
Biotechnology company AtheroNova (Other OTC :AHRO) said on Tuesday that it has filed pre-Investigational New Drug (pre-IND) documents using a patented bile acid in combination with a statin for the treatment of patients who fail to reach their LDL cholesterol target with statin treatment alone.
AtheroNova Announces Pre-IND Filing Under Section 505(b)(2)
GlobeNewswire - Tue Jul 15, 7:22AM CDT
AtheroNova Inc. (OTCBB:AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announced that it has filed pre-Investigational New Drug (pre-IND) documents with the US Food and Drug Administration (the "FDA"
under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act (the "Act" using a patented bile acid, in combination with a statin for the treatment of patients who fail to reach their LDL cholesterol target with statin treatment alone. The Company has received its initial pre-IND file number from the FDA indicating the initiation of the review process. Section 505(b)(2) of the Act specifically allows the FDA to rely on data not developed by the applicant company for approval of a New Drug Application ("NDA" for their intent to use previously approved active ingredient(s) in a combination product or for a new indication not previously approved. AtheroNova Announces 2013 Financial Results
GlobeNewswire - Thu Mar 06, 8:23AM CST
AtheroNova Inc. (OTCBB:AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announced its financial results for the year-ended December 31, 2013 and is providing a corporate update on operations and progress on lead candidate AHRO-001.
AtheroNova Announces Preliminary Positive Phase 1 Clinical Data From Lead Drug AHRO-001, a Potential Treatment for Atherosclerosis
GlobeNewswire - Thu Feb 27, 8:52AM CST
AtheroNova Inc. (OTCBB:AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announced the release of preliminary findings from its Phase 1 clinical trial with its lead compound, AHRO-001. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.
Liberty Software and VUCA Health Partner to Enhance Patient Safety and Provide Pharmacies with an Innovative Patient Engagement Tool
PR Newswire - Fri Jan 17, 8:08AM CST
VUCA Health, which has created the largest and most robust medication video library in the world to address health literacy, announced today that Liberty Software, a leading pharmacy management solution focused on innovation and customer service, will offer the MedsOnCue solution to its base of pharmacies.
Global Microspheres Market Report 2013 - Global Trends & Forecasts to 2018
PR Newswire - Wed Jan 08, 1:13PM CST
Research and Markets (http://www.researchandmarkets.com/research/6s2fj8/microspheres) has announced the addition of the "Global Microspheres Market Report 2013 - Global Trends & Forecasts to 2018" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
10-K: ESTERLINE TECHNOLOGIES CORP
Edgar Online - Fri Dec 20, 3:08PM CST
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations
Farmers Files Lawsuit Seeking More Than $3 Million Against Radiological Corporations And Their Owners For Allegedly Billing For Services Never Rendered
PR Newswire - Thu Dec 19, 10:32AM CST
Farmers Insurance Exchange®, 21st Century Insurance Company®, Coast National Insurance Company®, Mid-Century Insurance Company®, and Truck Insurance Exchange® ("Farmers"
have filed a lawsuit in the Superior Court of California against two radiological corporations and their owners alleging they prepared and submitted false and misleading documentation to receive payment for services never provided. The detailed civil complaint seeks restitution and additional remedies for alleged violations of California's Unfair Business Practices (Business and Professions Code 17200) as well as the Insurance Frauds Prevention Act (Insurance Code 1871.7), and an order directing Defendants to cease and desist from engaging in alleged improper billing practices. AtheroNova to Present at the 2013 Aegis Healthcare Conference in Las Vegas
PR Newswire - Thu Sep 19, 6:00AM CDT
AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announced that Chairman and CEO, Thomas W. Gardner, will present a corporate overview at the 2013 Aegis Capital Healthcare Conference. The presentation will take place at 9:00am PT on Saturday, September 28 at The Encore at Wynn in Las Vegas, NV.
AtheroNova Inc. Presenting at 15th Annual Rodman & Renshaw Investment Conference
Marketwire - Wed Sep 04, 12:08PM CDT
AtheroNova Inc. (OTCQB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announced it will be featured as a presenting company at the 15th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. AtheroNova will be presenting on Monday, September 9 at 12:05pm EDT. The conference is being held September 8-10, 2013, at the Millennium Broadway Hotel in New York City.
Medical Marijuana, Biotech and Precious Metals Micro-Caps Under the Radar
Marketwire - Tue Aug 27, 8:52AM CDT
Virtual Sourcing, Inc. (PINKSHEETS: PGCX) pursues business opportunities in fiberglass recycling and marketing manufactured products made from recycled fiberglass fibers, other fibers and virgin materials. PGCX has announced ambitious growth plans throughout the month of August. Read about them all at the following link: http://bit.ly/REPORTPGCX
OTC Daily Alert Stock Watch - AtheroNova Inc (OTCBB: AHRO )
WorldStockWire - Sat Aug 10, 8:00PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
AtheroNova, Amgen and More Leveraging Russian Initiatives to Grow Biotech Sector
ACCESSWIRE - Thu Jul 18, 9:00AM CDT
"Life is short, and the process is long." That's what Cleveland BioLabs (NASDAQ: CBLI) President Dr. Michael Fonstein told Forbes last year while discussing the U.S. Food and Drug Administration's regulatory process. Cleveland BioLabs shifted the development of several of their drugs from the U.S. to Russia, the birthplace of the company and a land where regulations are more flexible, in order to expedite the process towards commercialization.
AtheroNova's AHRO-001 Targets Much More than Cholesterol, Shows New UCLA Study
ACCESSWIRE - Tue Jul 02, 9:52AM CDT
Metabolic Syndrome ("MS"
affects approximately a quarter of the U.S. population, according to a 2002 National Health and Nutrition Examination Survey. Characterized by raised triglycerides, reduced HDL cholesterol, high BMI/waistline, raised blood pressure, and raised fasting plasma glucose, the syndrome significantly increases the risk of heart disease and a host of other health problems, including stroke, diabetes and some common forms of cancer. AtheroNova Announces Publication of Positive Pre-Clinical Results with AHRO-001 in the FASEB Journal
PR Newswire - Thu Jun 27, 7:00AM CDT
AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announced publication of the preclinical study that supported the clinical development of the Company's investigational AHRO-001 drug. The study, which was conducted by scientists at the David Geffen School of Medicine, University of California Los Angeles, was published in the June 10, 2013 online issue of the FASEB Journal in advance of the print issue.
AtheroNova Inc initiates Phase 1 clinical trial of AHRO-001 for the potential treatment of atherosclerosis
M2 - Wed Jun 26, 6:45AM CDT
Biotech company AtheroNova Inc (OTC Markets:AHRO) reported on Tuesday the launch of its milestone Phase 1 clinical trial with its lead compound, AHRO-001, for the potential treatment of atherosclerosis.
Combining Therapies to Amplify the Effects of Statins
ACCESSWIRE - Wed Jun 12, 8:51AM CDT
Statins, drugs that improve blood cholesterol levels by inhibiting the liver enzyme HMG Co-A reductase, are some of the most widely prescribed drugs in the United States. Increasing diabetes and obesity rates are real problem, resulting in doctors working the script pad like never before in the last decade. Three of the 20 best-selling drugs of all-time are statins used in the treatment of dyslipidemia, a condition where a person has an abnormally high amount of lipids (cholesterol or fat) in their blood.
AtheroNova Announces Shipment of Phase 1 Drug Product
PR Newswire - Thu May 30, 7:01AM CDT
AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and to improve lipid profiles in humans, today announced that it has shipped the necessary clinical supplies of AHRO-001 to its Russian licensing partner, CardioNova. This drug product shipment is the last major step prior to kickoff of a Phase I human clinical trial. The shipment has set forth a timeline with patient screenings and first-in-man dosing in June.
AtheroNova Mentioned by Analyst in Life Sciences Report
ACCESSWIRE - Fri May 24, 8:15AM CDT
Mont Blanc Capital Equity Research issued a research update on May 14, 2013 for AtheroNova Inc. (OTC Markets: AHRO). In the report, the analyst maintained its Buy rating and $2.00 per share price target, while projecting that Phase I clinical trials would begin next month after the company received approval from the Russian Ministry of Healthcare (Minzdrav).
